Skip to main content
Premium Trial:

Request an Annual Quote

PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

NEW YORK – Dutch molecular diagnostics developer PathoFinder has received CE IVD marking for two multiplex PCR tests for SARS-CoV-2 and other respiratory pathogens.

Specifically, the Maastricht-based firm obtained CE marking for the RespiFinder 2Smart kit for SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS-CoV) testing, as well as for the RealAccurate Quadriplex (RAQ) Flu/COVID-19 PCR kit.

PathoFinder said that the RespiFinder 2Smart kit now detects 24 respiratory pathogens simultaneously using the company's proprietary 2SmartFinder technology. The SARS-CoV-2 N gene and MERS-CoV E gene were selected as targets to detect these additional viruses.

Meanwhile, the RAQ Flu/COVID-19 PCR kit detects and differentiates influenza A, influenza B, and SARS-CoV-2 (using the N gene and RdRp gene) from nasopharyngeal swabs.

PathoFinder received CE marking in April for its RealAccurate Quadruplex Corona-plus PCR kit for detecting SARS-CoV-2 from nasopharyngeal and oropharyngeal swabs, and in June for its RealAccurate Quadruplex SARS-CoV-2 PCR kit for detecting viral RNA by targeting the N and RdRp genes.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.